The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. ALCL is a rare form of non-Hodgkin lymphoma
The approval enables to use of ligelizumab to treat CSU, also called chronic idiopathic urticaria (CIU), in patients who have an inadequate response to H1-antihistamine treatment. CSU is
“The acquisition of Kashiv Specialty aligns strongly with our Amneal 2.0 growth strategy which we expect will deliver substantial value for our Specialty and Generics businesses,” said Chirag
VIR-7832, a neutralising Covid-19 antibody, attaches to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1. According to GSK, the preclinical data suggests that VIR-7832 has two distinguishing
This new 103,720 ft2 facility will support clinical development of Rocket’s growing pipeline of lentivirus (LV) and adeno-associated virus (AAV) gene therapies from discovery through pivotal trials, with
As per terms of the deal, Kymab will secure an upfront payment of up to $1.1bn from Sanofi. Kymab is also eligible to secure up to $350m based
Upon the closing of the transaction, which is expected to occur in the second quarter of 2021, GX Acquisition Corp. will be renamed Celularity Inc., and its common
The company has pooled funds in a financing round co-led by new investors Rock Springs Capital and Foresite Capital. Other new investors consist of T. Rowe Price, Wellington
The phase III randomised, double-blind, placebo-controlled, two-arm, parallel-group and multi-centre study will assess safety, tolerability and clinical benefit of the company’s human recombinant alkaline phosphatase to treat patients
A Phase I study with INV-101 is currently ongoing to evaluate its safety, tolerability and pharmacokinetics profile. “The RPD designation is an important recognition for Inversago, highlighting the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.